急性白血病临床试验中种族和民族入组差异及人口统计报告要求
该研究分析了2002至2017年美国急性髓系白血病(AML)和急性淋巴细胞白血病(ALL)临床试验的人口统计学报告和入组多样性,发现少数种族和民族患者入组显著低于非西班牙裔白人,且联邦报告要求实施后报告比例有所提高但多样性未改善。
要点
- 少数种族和民族患者入组显著低于非西班牙裔白人。
- 联邦报告要求实施后种族报告比例提高,但种族-民族联合报告未变。
- 需针对急性白血病制定入组多样化策略。
核心结论
- 急性白血病临床试验的人口统计学入组报告不理想,报告要求实施后多样性变化可能源于既往未报告的入组差异。
研究设计与样本
- 回顾性分析2002至2017年美国223项AML试验和97项ALL试验的ClinicalTrials.gov数据。
主要发现
- 223项AML试验中68项(30.5%)报告了种族和民族,97项ALL试验中51项(52.6%)报告了种族和民族。
临床怎么用
- 需针对急性白血病制定特定的入组多样化策略以改善临床试验代表性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Data regarding racial and ethnic enrollment diversity for acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL) clinical trials in the United States are limited, and little is known about the effect of federal reporting requirements instituted in the late 2000s. We examined demographic data reporting and enrollment diversity for ALL and AML trials in the United States from 2002 to 2017, as well as changes in reporting and diversity after reporting requirements were instituted. Of 223 AML trials and 97 ALL trials with results on ClinicalTrials.gov, 68 (30.5%) and 51 (52.6%) reported enrollment by both race and ethnicity. Among trials that reported race and ethnicity (AML, n = 6554; ALL, n = 4149), non-Hispanic (NH)-Black, NH-Native American, NH-Asian, and Hispanic patients had significantly lower enrollment compared with NH-White patients after adjusting for race-ethnic disease incidence (AML odds ratio, 0.68, 0.31, 0.75, and 0.83, respectively; ALL odds ratio, 0.74, 0.27, 0.67, and 0.64; all, P ≤ .01). The proportion of trials reporting race increased significantly after implementation of the reporting requirements (44.2% to 60.2%; P = .02), but race-ethnicity reporting did not (34.8% to 38.6%; P = .57). Reporting proportions according to number of patients enrolled increased significantly after the reporting requirements were instituted (race, 51.7% to 72.7%; race-ethnicity, 39.5% to 45.4%; both, P < .001), and relative enrollment of NH-Black and Hispanic patients decreased (AML odds ratio, 0.79 and 0.77; ALL odds ratio, 0.35 and 0.25; both P ≤ .01). These data suggest that demographic enrollment reporting for acute leukemia trials is suboptimal, changes in diversity after the reporting requirements may be due to additional enrollment disparities that were previously unreported, and enrollment diversification strategies specific to acute leukemia care delivery are needed.
引用
- Hantel A, Luskin MR, Garcia JS, et al. Racial and ethnic enrollment disparities and demographic reporting requirements in acute leukemia clinical trials. Blood Adv. 2021. PMID: 34473244. doi:10.1182/bloodadvances.2021005148
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。